By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


Company News
Boehringer Ingelheim Corporation Release: First Patients Enrolled In Study To Evaluate Dabigatran Etexilate After PCI With Stenting 8/19/2014 10:19:19 AM
FDA Tentatively Approves Boehringer Ingelheim Corporation, Eli Lilly and Company (LLY)'s Basaglar™ 8/18/2014 3:54:05 PM
Boehringer Ingelheim Corporation Goes On A Hiring Freeze And Plans To Chop Jobs 8/12/2014 6:13:33 AM
Medivir AB (MVRBF) Licenses Respiratory Syncytial Virus Drug Program From Boehringer Ingelheim Corporation 8/4/2014 11:04:25 AM
Zealand Pharma  (ZEAL.CO), Boehringer Ingelheim Corporation Strike $402 Million Peptide Pact 7/28/2014 9:06:40 AM
Boehringer Ingelheim Corporation Release: Benefits And Safety Of Pradaxa® (Dabigatran Etexilate Mesylate) Repeatedly Confirmed 7/24/2014 9:12:38 AM
Boehringer Ingelheim Corporation's Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation 7/16/2014 10:38:47 AM
Boehringer Ingelheim Corporation's Breakthrough Cancer Drug Volasertib Effective In Phase 2 Trial 7/8/2014 8:38:37 AM
Boehringer Ingelheim Corporation Submits Applications In Europe For Tiotropium + Olodaterol Respimat® Fixed-Dose Combination In COPD 7/2/2014 10:54:41 AM
U.S. FDA Accepts NDA Filing For Boehringer Ingelheim Corporation's Investigational Nintedanib And Grants Priority Review Designation For The Treatment Of Idiopathic Pulmonary Fibrosis 7/2/2014 8:44:20 AM